The abstract is read at the publisher; the summary is JClub's.
Host transcriptomics is the strongest biomarker evidence for short-term progression risk in tuberculosis, but no biomarker consistently meets WHO target product profile accuracy thresholds.
- Why it matters: Evidence for tuberculosis biomarkers is fragmented and review quality varies, leaving uncertainty about which markers can reliably detect disease, forecast progression, or guide treatment.
- What they did: An umbrella review searched MEDLINE, Web of Science, Global Index Medicus, and the Cochrane Library to Sept 1, 2025, appraised 46 systematic reviews with an adapted AMSTAR-2, and narratively synthesized nine biomarker classes plus quantitative prioritisation.
- The result: Across detection, progression, and treatment monitoring, accuracy estimates were highly variable and primary studies often had high selection bias, implying limited readiness and a need for prospective head-to-head studies in representative populations.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.